Skip to main content
. 2017 Feb 19;8(15):24437–24448. doi: 10.18632/oncotarget.15510

Figure 3. CFTR inhibition down-regulated the expression and activity of BCR-ABL and canonical Wnt/β-catenin signaling in CFTR-high Ph+ acute leukemia cells.

Figure 3

(A) CFTRinh-172 and imatinib down-regulated CFTR, BCR-ABL and classic Wnt/β-catenin signaling in K562 cells. (B) CFTR shRNA induced a similar effect on CFTR, BCR-ABL and classic Wnt/β-catenin signaling in K562 cells compared with CFTRinh-172. (C) CFTRinh-172 and imatinib down-regulated CFTR, BCR-ABL and classic Wnt/β-catenin signaling in SUP-B15 cells. (D) CFTRinh-172 and imatinib down-regulated CFTR, BCR-ABL and classic Wnt/β-catenin signaling in a Ph+ B-ALL primary sample.